Abbott Laboratories (ABTT34)
Bovespa
41.88
-0.57 (-1.34%)
Closed
Oct 5, 2026
Day's Range
40.7742.45
52 wk Range
33.5060.92
Financial Statements - ABTT34 - Abbott Laboratories
Revenue
44.32B▼ 80.1%
Net Income
6.52B▼ 90.8%Net Margin 14.7%
EBITDA
12.02B▼ 78.9%
Free Cash Flow
7.39B▼ 78.0%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 44.32B | 222.20B | 40.10B | 43.65B | 43.07B | 34.60B |
| Cost of Goods | 19.31B | 99.08B | 17.97B | 19.14B | 18.53B | 15B |
| Gross Profit | 25B | 123.12B | 22.13B | 24.51B | 24.53B | 19.60B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 8.05B | 36.15B | 6.47B | 8.36B | 8.42B | 5.35B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 598M | 2.13B | 438M | 319M | 276M | 111M |
| Pre Tax Income | 8.46B | 37.14B | 6.66B | 8.30B | 8.21B | 4.96B |
| Income Tax | 1.94B | -33.84B | 941M | 1.37B | 1.14B | 497M |
| Net Income | 6.52B | 70.98B | 5.72B | 6.93B | 7.07B | 4.49B |
| EPS Basic | 0.313064 | 0.644935 | 0.273333 | 0.328333 | 0.330833 | 0.21 |
| EPS Diluted | 0.31 | 0.636667 | 0.271667 | 0.325833 | 0.328333 | 0.208333 |
| Basic Shares Outstanding | 20.83B | 110.07B | 3.64B | 3.65B | 3.69B | 3.69B |
| Diluted Shares Outstanding | 20.83B | 110.07B | 3.64B | 3.65B | 3.69B | 3.69B |
| Ebit | 8.95B | 40.10B | 7.30B | 8.86B | 8.74B | 5.51B |
| Ebitda | 12.02B | 57.01B | 10.58B | 12.13B | 12.28B | 8.83B |
| Net Income Continuous Operations | 6.52B | 70.98B | 5.72B | 6.93B | 7.07B | 4.49B |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
